Soligenix, Inc.
SNGXHealthcare|Biotechnology|US
$0.34
+0.00 (+0.51%)
DCF Value
$1.27
Tangible Book / Share
$0.39
Cash / Share
$0.57
Clinical Trials (12)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT02448381 FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) | Cutaneous T-Cell Lymphoma | P3 | Completed | 169 | RCT, Double-blind | SGX301 (synthetic hypericin), Placebo |
| NCT06470451 Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL | CTCL/ Mycosis Fungoides, CTCL | P3 | Terminated | 70 | RCT, Double-blind | Hypericin, Placebo |
| NCT00926575 Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD) | Acute Gastrointestinal Graft vs Host Disease | P3 | Terminated | 140 | RCT, Double-blind | oral beclomethasone 17,21-dipropionate, Placebo |
| NCT03237325 DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer | Squamous Cell Carcinoma of the Oral Cavity and Oropharynx, Oral Mucositis | P3 | Completed | 266 | RCT, Double-blind | SGX942, Placebo |
| NCT05380635 PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma | Cutaneous T-Cell Lymphoma/Mycosis Fungoides | P2 | Completed | 9 | Open-label | Hypericin |
| NCT02013050 A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer | Oral Mucositis | P2 | Completed | 111 | RCT, Double-blind | SGX942, Placebo |
| NCT06149247 HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL | Cutaneous T-Cell Lymphoma/Mycosis Fungoides | P2 | Completed | 10 | RCT, Open-label | Hypericin, Mechlorethamine Topical Gel |
| NCT05442190 Topical SGX302 for Mild-to-Moderate Psoriasis | Psoriasis, Plaque Psoriasis | P2 | Completed | 15 | RCT, Double-blind | Hypericin |
| NCT01925950 Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD) | Chronic Gastrointestinal Graft vs Host Disease | P2 | Terminated | 2 | RCT, Double-blind | orBec, Placebo |
| NCT01073384 A Dose Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal Cancer | Enteritis | P1P2 | Completed | 16 | RCT, Open-label | SGX201 (delayed release beclomethasone 17,21-dipropionate) |
| NCT05872854 Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light | Cutaneous T Cell Lymphoma, Mycosis Fungoides | P2 | Completed | 10 | Open-label | Hypericin |
| NCT06386744 Dusquetide for the Treatment of Behcet's Disease | Behçet Disease | P2 | Completed | 8 | Open-label | Dusquetide |